Wednesday, November 14, 2012
ImmuneWorks Inc., of Indianapolis, said it completed a Phase I trial of Type V Collagen oral solution (IW001) in patients suffering from idiopathic pulmonary fibrosis. Thirty patients were enrolled in the 24-week study, which showed the drug to be well tolerated in preliminary results, with effects on lung function.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.